Empagliflozin NEW

$0.00 1KG

$0.00 25KG

Min. Order1KG
Purity99.5%min
Cas No864070-44-0
Supply Ability100KGS
Update time2025-12-25

Wuhan Fortuna Chemical Co., Ltd

VIP5Y

China

Enterprise Verified

Business Bank account Basic Contact Infomation Business Address Trade Company

Chemical Properties

Product Name	Empagliflozin
CAS No	864070-44-0
EC-No	620-176-8
Min. Order	1KG
Purity	99.5%min
Supply Ability	100KGS
Release date	2025/12/25

Empagliflozin Cas 864070-44-0

Specification

Items	Specifications	Results
Appearance	White to almost white powder	White powder
Identification	HPLC. Retention time of main peak in Sample solution corresponds to that in reference solution,as obtained in test of isomer.	Complies
Identification	IR.The IR spectrum is consistent with that obtained with the reference	Complies
Water	≤0.5%	0.07%
Isomer	X0187-IMP06≤0.10%	0.03%
Residue on ignition	Not more than 0.1%	0.06%
Related substances	X0187-IMP01≤0.10%	Not detected
	X0187-IMP02≤0.10%	Not detected
	X0187-IMP04≤0.10%	＜LOQ:0.04%
	Any other individual impurity≤0.10%	0.02%
	Total impurities≤0.5%	0.08%
Residual solvents	Toluene≤890ppm Tetrahydrofuran≤720ppm Acetonitrile≤410ppm Dichloromethane≤600ppm	161ppm 75ppm Not detected Not detected
Assay(on anhydrous basis)	98.0%~102.0%	99.5%
Conclusion	The product conforms to the above specifications.

Welcome to contact with us to get more information.

Empagliflozin (sold under the brand name Jardiance, among others) is a prescription medication belonging to a class of drugs called SGLT2 inhibitors (Sodium-Glucose Co-Transporter 2 Inhibitors).

How It Works:

It works primarily in the kidneys. Normally, your kidneys reabsorb glucose back into the bloodstream. Empagliflozin blocks the SGLT2 protein, causing the kidneys to excrete excess glucose through urine. This effectively lowers blood sugar levels.

Approved Medical Uses

Empagliflozin is FDA-approved and widely used for several important conditions:

1. Type 2 Diabetes Mellitus

Primary Use: To improve glycemic (blood sugar) control in adults with type 2 diabetes, alongside diet and exercise.
Key Feature: Its action is insulin-independent, meaning it works regardless of the body's insulin production or resistance. It also carries a low risk of hypoglycemia (low blood sugar) when used alone.

2. Cardiovascular Risk Reduction

Landmark Use: To reduce the risk of major cardiovascular events (e.g., heart attack, stroke) in adults with type 2 diabetes who have established cardiovascular disease.
This was a groundbreaking finding, showing empagliflozin provided significant heart protection.

3. Heart Failure

For Heart Failure with Reduced Ejection Fraction (HFrEF): To reduce the risk of cardiovascular death and hospitalization for heart failure in adults (with or without type 2 diabetes).
For Heart Failure with Preserved Ejection Fraction (HFpEF): To reduce the risk of cardiovascular death and hospitalization for heart failure in adults.

4. Chronic Kidney Disease (CKD)

To reduce the risk of sustained progression of kidney disease, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease (with or without type 2 diabetes).

Key Benefits & Effects

Lowers Blood Sugar: Effectively reduces HbA1c levels.
Promotes Weight Loss: Excreting glucose means losing calories, leading to modest weight reduction.
Lowers Blood Pressure: Causes mild diuresis (fluid loss), which can help reduce blood pressure.
Cardio-Renal Protection: Its most significant benefits are protecting the heart and kidneys, making it a cornerstone therapy for patients with diabetes, heart failure, or CKD.

Important Safety Information & Side Effects

Common Side Effects:

Genital yeast infections (due to increased sugar in urine).
Urinary tract infections (UTIs).
Increased urination.
Possible dehydration, leading to dizziness or lightheadedness.

Serious Warnings (Black Box Warning):

Risk of Ketoacidosis: Rare but serious cases of euglycemic diabetic ketoacidosis (high ketones with normal or slightly high blood sugar) have occurred, sometimes in people with type 1 diabetes (for which it is not approved). Symptoms include nausea, vomiting, abdominal pain, tiredness, and trouble breathing.

Other Serious Risks:

Necrotizing Fasciitis of the Perineum (Fournier's Gangrene): A rare, severe bacterial infection of the genital area.
Lower Limb Amputation: An increased risk was observed with a related drug (canagliflozin); risk with empagliflozin is less clear but remains a consideration.
Bone Fracture Risk: Potential increased risk.
Acute Kidney Injury: Risk is increased, especially with dehydration.

Administration

Usually taken once daily in the morning, with or without food.
Dosing depends on the condition being treated (e.g., 10 mg or 25 mg for diabetes, 10 mg for heart failure/CKD).

Crucial Disclaimer: This information is for educational purposes only. Empagliflozin is a potent medication that must be prescribed and managed by a qualified healthcare professional who can assess your individual health profile, risks, and benefits. Always consult your doctor for medical advice.

Packages